Dapagliflozin ameliorates myocardial ischemia/reperfusion injury by modulating EGFR signaling and targeting NCOA4-mediated ferritinophagy

Key Points

• Dapagliflozin significantly reduces myocardial ischemia/reperfusion injury, improving heart function and tissue integrity.
• Treatment with dapagliflozin led to a notable enhancement in EGFR signaling pathways, critical for cellular recovery.
• Research was based on a comprehensive analysis of myocardial tissue samples, assessing biochemical and physiological responses.
• These findings highlight the potential of dapagliflozin as a therapeutic candidate in myocardial injury management.